Canada Plans Parallel HTA And Marketing Authorization Reviews
Executive Summary
Canada plans to run regulatory reviews and health technology appraisals in parallel for certain new medicines. This could mean some companies get their drugs listed on public health plans almost immediately upon market authorization, rather than having to wait for more than a year.
You may also be interested in...
Canada To Speed Market Access With Aligned HTA And Marketing Authorization Reviews
Drug sponsors can opt into the newly launched Canadian parallel review scheme at any stage of the marketing authorization review process, but the earlier they do so the better.
Canada Plans Drug Price Reductions By Changing Reference Country List
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.